# Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

> **NCT05608213** · PHASE3 · RECRUITING · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 187 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **PROCEDURE:** Lenvatinib Plus I-125 Seed Brachytherapy
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT05608213
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-02
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-12-01
- **Target enrollment:** 187 (ESTIMATED)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05608213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05608213, "Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05608213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*